Stock of KalVista Pharmaceuticals, Inc. (KALV) is dropping 7 percent on Thursday morning after the announcement of changes in management.
The company announced the resignation of Andrew Crockett from the Chief Executive Officer position. He will be replaced by KalVista's current CFO and CBO Benjamin Palleiko.
Currently, KalVista's stock is dropping 7.61 percent, to $13.28 over the previous close of $14.38 on a volume of 244,031 on the Nasdaq.
The pharmaceutical company also said that it plans to file for a New Drug Application for sebetralstat in the U.S. and Japan during the first half and second half, respectively, of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.